Featuring: Itaconix PLC (ITX), Quartix Technologies plc (QTX), Eden Research PLC (EDEN) and Bioventix plc (BVXP)
Itaconix is a leading innovator in sustainable plant-based polymers used to decarbonise everyday products. They use a proprietary technology platform to produce and sell specialty ingredients and formulations that improve the safety, performance, and sustainability of over 160 products.
Their customers partner with them to define product claims that win in the marketplace, create formulations that enable the claims, and successfully deliver safer, high performing and cost-effective formulations and ingredients.
The company’s current ingredients are enabling and leading new generations of products for cleaning surfaces, fabrics, dishware, air, kitchens, bathrooms, and industrial applications.
Presenter: John Shaw- Chief Executive Officer
As a founder, John Shaw has driven the direction and growth of Itaconix Corporation since 2008. He has over 25 years of experience in senior management roles in the pharmaceutical, biomedical, and specialty chemical sectors and brings significant marketing, strategy, and business management expertise along with a broad technical understanding to Itaconix’s management team. John assumed the role of Chief Executive Officer when he joined the Board on 12 July 2018. John began his career holding a number of increasingly senior roles at SmithKline Beecham, Westaim, and Mitek Systems, Inc. He has a BA in Economics from Pomona College and an MBA from Harvard Business School.
Quartix Technologies plc
Quartix provides commercial fleet tracking for cars, coaches, trucks and vans throughout the UK, the US and Europe. With trackers installed in over 600,000 vehicles, Quartix helps more than 20,000 businesses cut costs and improve productivity every day.
The award-winning GPS vehicle tracking system offers a host of valuable tools for fleet managers, including driver timesheets, driver behaviour analysis and geofencing alerts. Quartix’s unique Safe Speed feature also compares each driver’s speed with that of other road users on the same stretch of road. Managers can use this information to help their drivers maintain a good driving style, appropriate for the roads they are travelling, while adhering to the legal speed limits.
Founded in 2001 by four industry professionals, the company’s founder and CEO, Andy Walters, is still with the business today. Industries using the Quartix system range from construction, security, manufacturing, retail, landscaping and trades services.
Presenter: Andy Walters- Executive Chairman
Andy Walters founded Quartix in 2001 with three colleagues. Prior to that he was Managing Director of a subsidiary of Spectris plc for 6 years and had spent 15 years with Schlumberger in the UK and France, where he was marketing director of the payphones and smart cards division. Andy holds an MA in electrical sciences from the University of Cambridge.
Eden Research PLC
Eden Research is the only UK-quoted company focused on biopesticides for sustainable agriculture. It develops and supplies innovative biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries.
Eden’s products are formulated with terpene active ingredients, based on natural plant defence metabolites. To date, they have been primarily used on high-value fruits and vegetables, improving crop yields and marketability, with equal or better performance when compared with conventional pesticides. Eden has three products currently on the market:
- Mevalone®: a foliar biofungicide which initially targets a key disease affecting grapes and other high-value fruit and vegetable crops.
- Cedroz™: a bionematicide that targets free living nematodes which are parasitic worms that affect a wide range of high-value fruit and vegetable crops.
- Ecovelex®: a biological bird-repellent seed treatment initially used on maize, with further crop seeds to be added in the future.
Eden’s Sustaine® is the underlying yeast-based, plastic-free microencapsulation technology behind these three formulations used, to harness the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes).
Eden was awarded the London Stock Exchange Green Economy Mark in January 2021, which recognises London-listed companies that derive over 50% of their total annual revenue from products and services that contribute to the global green economy. Eden derives 100% of its total annual revenues from sustainable products and services.
Sean Smith- Chief Executive Officer
Sean Smith is the Chief Executive Officer of Eden Research, a role that he has held since September 2014.
Sean has a bachelor’s degree in microbiology and over 25 years of experience in the speciality chemicals and industrial biotechnology industries. He has held senior commercial leadership roles ranging from sales and marketing to business management and intellectual property licensing in blue-chip companies such as Ciba (now BASF) and Honeywell. In recent years, Sean has focussed on technology commercialization through licensing and company formation working with Intellectual Ventures and several start-ups.
Alex Abrey- Chief Financial Officer
Alex Abrey is the Chief Financial Officer of Eden Research. He joined the company in September 2007.
Alex, a Chartered Certified Accountant, joined Eden Research, having been a Chief Accountant to the company for the previous four years. He has acted as Financial Director to a diverse range of businesses including a financial and management consultancy business based in Oxfordshire, a medical waste management company and an intellectual property licensee involved in plastics manufacturing. Alex has over 20 years’ experience in both practice and industry.
Bioventix creates, manufactures and supplies high affinity sheep monoclonal antibodies (SMAs) for use in diagnostic applications. Bioventix antibodies are preferred for use when they confer an improved test performance compared to other available antibodies.
Most of our antibodies are used on blood-testing machines installed in hospitals and other laboratories around the world. Bioventix makes antibodies using our SMA technology for supply to diagnostic companies for subsequent manufacture into reagent packs used on blood-testing machines. These blood-testing machines are supplied by large multinational in vitro diagnostics (IVD) companies such as Roche Diagnostics, Siemens Healthineers, Abbott Diagnostics & Beckman Coulter. Antibody-based blood tests are used to help diagnose many different conditions including, amongst others, heart disease, thyroid function, fertility, infectious disease and cancer.
Peter Harrison- CEO
Peter is 65 years old and has ~30 years’ experience of antibody technology at Celltech, KS Biomedix & Bioventix.
Priority booking will be given to Full members for this event. There are limited spaces available, so we may not be able to open this up to Associates. If you wish to guarantee yourself a place, please upgrade to Full membership (£45p.a.) in order to register now.
If spaces remain, we will allow Associate bookings from 14th of February, which will be processed on a first-come, first-served basis.
Stockopedia will provide facts and figures on the presenting companies for attendees (don’t forget that ShareSoc subscribing members can get a special discount on Stockopedia subscription rates – see Member Offers)
Event registration opens at 4.00 pm and presentations commence at 4.30 pm.
If you are already a full member of ShareSoc, you must log in prior to registering, then just click “SUBMIT” below.
This seminar is for Full and Combined Members only. We may open this event up to Associate members if there are spaces remaining nearer to the event date, but to guarantee a place, please join as a Full member here or upgrade your membership here. Once you have joined or upgraded, please allow up to 72 hours to receive your welcome pack and login instructions to allow you to register.
Click here for help on logging in.